Next week, >10,000 Fatty Liver stakeholders are expected to journey to London (rail strike and all) for the International Liver Congress (#ILC2022), the first meeting at this level since the pandemic started to include an in-person attendance option. This week, NASH Tsunami identifies some of the most important and intriguing non-embargoed presentations at #ILC2022. This conversation continues our discussion of OS044, NAFLD patients have worse health-related QoL compared to the general population irrespective of their fibrosis stage: results from a prospective multicenter UK study, from Margarita Papatheodoridi (UK) and discusses THU051, Health-related quality of life is impaired in people living with HIV and hepatic steatosis from Maurice Michel (DE).
Highlighting Intriguing ILC2022 Abstracts: More on NAFLD Quality of Life
This conversation starts by picking up on the far-ranging discussion of quality-of-life that ends Episod 30.2. It starts with Roger making two points: one about the impact that clinician/clinical trial design consultants can have on bringing quality-of-life endpoints to a more central role in Phase 3 trials and another that drug revenue forecasts might grow if forecasters integrate the impact of quality-of-life metrics into the target patient population. Louise notes the secondary impact of quality-of-life of work days lost and quality of work time. Jörn mentions THU051, a paper from his group that focuses on similar quality-of-life issues in patients with NAFLD living with HIV as well.